KEY POINTS
==========

-   **Question:** Is severe Coronavirus Disease 2019 (COVID-19) disease associated with an immunosuppressive phenotype of key innate immune cells?

-   **Findings:** We observed considerable reduction of monocytic human leukocyte antigen-DR (mHLA-DR), a key marker of monocytic immune function, in critically ill COVID-19 patients with acute respiratory failure and this effect remained unchanged over the first days on the intensive care unit (ICU).

-   **Meaning:** Severe COVID-19 disease is associated with reduced human leukocyte antigen (HLA-DR) expression on circulating cluster of differentiation (14+) (CD14+) cells, indicating a dysfunctional immune response. Future strategies aiming for immunomodulation in this population of ICU patients should be guided by an immune-monitoring program in an effort to determine who might potentially benefit from a targeted immunological intervention.

In higher life forms, the immune system is organized in complex social network architecture-like structures,^[@R1]^ and its dysfunction is associated with adverse outcomes in various clinical scenarios. Although detection and monitoring of various organ dysfunctions is a key challenge for physicians involved in the care for the critically ill, the immune system may currently be regarded somewhat overlooked as it is typically not monitored within the clinical routines of most intensive care units (ICUs). This may be of particular importance in critically ill patients with severe infections (eg, patients with bacterial septic shock).^[@R2]--[@R7]^

Data show that monocytes/macrophages play key roles in critically ill patients with severe infections and constitute a first-line cellular responsethat initiates and promotes a targeted, that is, adaptive, immune response.^[@R2],[@R3],[@R8]^ In this regard, flow cytometry--based standardized assessment of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR) was proposed by us and others^[@R2],[@R9],[@R10]^ to serve as a global marker of (monocytic) immune function as it reflects key cell--mediated immune functions including major histocompatibility complex (MHC) class II--mediated antigen-presentation, ex-vivo cytokine release, and phagocytosis.^[@R2],[@R3],[@R6],[@R8],[@R10]^ mHLA-DR expressioncan be assessed in a quantitative fashion using a standardized assay (coefficient of variation \<4% intralab and 15% interlab),^[@R11]^ allowing for multicenter data comparison.^[@R9]^ Importantly, mounting data from critically ill patients with (bacterial) sepsis/septic shock show that reduced mHLA-DR expression (indicating "injury-associated immunosuppression"^[@R3]^) is associated with adverse clinical outcomes in ICU patients, including increased rates of secondary infections and increased mortality.^[@R2],[@R12]--[@R15]^ Further, mHLA-DR previously served to guide targeted immunological interventions, for example, using immunostimulatory approaches^[@R16]--[@R18]^ or via reduction of inhibitory factors.^[@R19]^ Such biomarker enrichment^[@R20]^ may allow for identification of which patient might benefit best from a given immunomodulatory intervention.^[@R2],[@R6],[@R7],[@R14]^

From an epidemiological perspective, Coronavirus Disease 2019 (COVID-19;severe acquired respiratory syndrome coronavirus-2 \[SARS-CoV-2\]) patients appear (clinically) well characterized.^[@R21]--[@R24]^ However, the role of virus-induced immunosuppression remains incompletely understood.^[@R25]^ We therefore embarked to investigate the role and course of mHLA-DR expression inICU patients with severe COVID-19 disease, that is, critically ill patients. This is performed as understanding of the immunologic phenotype will be important, for example, when immunomodulatory immunotherapies are evaluated.

Methods
=======

In a preliminary prospective monocentric observational study, patients with confirmed COVID-19 disease were included from March toApril 2020 and followed up until ICU-/hospital discharge and/or death. Patients were initially assessed for eligibility in the emergency rooms (noncritically ill patients) or at the ICU (in cases of direct ICU admission). The study was performed in a 900+ bed tertiary care academic medical center (Inselspital, Bern University Hospital, Switzerland). In this center, the Department of Intensive Care Medicine is the sole provider of intensive care medicine for adults.

Adult (aged ≥18 years) patients with confirmed SARS-CoV-2 infection (detected by polymerase chain reaction \[PCR\] in nasopharyngeal swabs) were consecutively included in the study after provision of informed consent (in case of lack of capacity and/or inability to provide consent, consent followed the local procedures for research projects in emergency situations). Screening of patients was performed in daily clinical practice by the research team. The following exclusion criteria applied: no confirmed SARS-CoV-2 infection or confirmed SARS-CoV-2 infection \>3 days before inclusion, age \<18 years, lack of consent. No financial compensation applied for participants. Hospitalized patients and ICU patients were followed up until ICU or hospital discharge or death (while in hospital). Laboratory data wererecorded with missing data indicated. Laboratory samples were drawn at the scheduled visits within ±36 hours. Data available until April 30, 2020 (censor date) wereincluded. The trial was performed in accordance with the "Declaration of Helsinki" and approved by the Kantonale Ethikkommission KEK, Bern, Switzerland, Nr. 2020-00877.

FlowCytometricAssessment of mHLA-DR Expression
----------------------------------------------

Flowcytometric assessment of mHLA-DR expression (primary outcome) was performed from ethylenediaminetetraacetic acid (EDTA) samples within 4 hours, as previously reported^[@R11]^ (discussed in references[@R3], [@R9]). In brief, a mixture that contains beads with predefined amounts of conjugated antibodies (phycoerythrinmolecules \[PE\]) is measured using the same fluorescence-activated cell sorting (FACS) instrument settings (as the cells of interest) using a mixture of antihuman HLA-DR-PE, antihuman CD14-PerCP-Cy5.5, and an inhibitor of HLA-DR turnover (Quantibrite HLA-DR/Monocyte reagent, Becton Dickinson, Franklin Lakes, NJ).^[@R11]^ The known ratio of PE to anti-HLA-DR antibody is applied to convert PE molecules/cell into antibodies/cell^[@R3],[@R9],[@R11]^ with the anti-CD14 antibody detecting all monocytes (CD14 bright and weak positive).^[@R11]^ The gating strategy is given in Figure [1](#F1){ref-type="fig"}.

![Flow cytometric analysis of HLA-DR expression in COVID-19 patients. Gating strategy: key steps in measurement of monocytic HLA-DR expression using standardized assessment. Beads are gated on their SSC and FSC characteristics (not shown), and PE fluorescence is plotted (A). Patient's monocytes are gated by CD14-binding and SSC properties (B), mHLA-DR expression is plotted against CD14 to calculate the median HLA-DR expression (C). CD14 indicates cluster of differentiation (14); COVID-19, Coronavirus Disease 2019; FSC, forward scatter; HLA-DR, human leukocyte antigen-DR; mHLA-DR, monocytic human leukocyte antigen-DR; PE, phycoerythrin; SSC, side scatter.](ane-publish-ahead-of-print-10.1213.ane.0000000000005044-g001){#F1}

Statistics
----------

Data were analyzed with Stata 16.1 (StataCorp, College Station, TX). The distribution of continuous data was assessed with histograms, Q-Q plots, and Shapiro-Wilk tests. All continuous data departed from the normal distribution and are presented as median \[quartiles\]. Baseline demographic data, laboratory data, and follow-up data were compared between the groups with Mann-Whitney *U* tests (continuous data) or with Fisher exact test (categorical data; all had expected counts \<5 in ≥25% of cells).

The primary outcome, mHLA-DR expression at admission, was compared between the groups (patients admitted to the general ward versus patients admitted to the ICU) using a Mann-Whitney *U* test.^[@R26]^ The median difference between the groups and its 95% confidence interval (CI)were estimated with the Hodges-Lehmann estimator. Being aware that our small dataset does not lend itself to multiple regression modeling, we yet performed explorative analyses to gauge potential confounding due to differences in baseline characteristics between groups.^[@R27],[@R28]^ We used quantile (median) regression, as well as linear regression with bootstrapped standard errors (10,000 replications), to adjust for age, sex, and body mass index (BMI).

One patient was first admitted to the normal ward and subsequently to the ICU after clinical deterioration. According to the primary admission, this patient is considered a noncritically ill patient for the comparison of mHLA-DR expression at admission. We also performed a sensitivity analysis in which the patient was analyzed as being an ICU patient.

In ICU patients, follow-up data for mHLA-DR expression were obtained at days 3 and 5 of their ICU admission. Differences over time were tested with the Skillings-Mack test. This test is an extension of the Friedman test (nonparametric equivalent to 1-way repeated-measures analysis of variance) that allows for missing data. Two-sided *P*\<.05 was considered statistically significant. For this preliminary investigation, a formal a priori power analysis/sample size calculation was not performed, and the sample size is based on the available number of patients.

Results
=======

Sixteen patients (12 male, median age 68 years) were included in this preliminary observational study, of which 9 were primarily admitted to the ICU for mechanical ventilation, and 7 with primary hospitalization at the general ward. TheTable shows demographic data, comorbidities, laboratory data, as well as follow-up data for both patient groups. While the Tablesuggests clinically relevant differences in terms of infection parameters and length of hospital stay in our sample of patients, there was insufficient evidence to claim a significant difference in the population of patients from which the data were sampled (all *P*values \>.05).

###### 

Baseline Demographics, Disease Severity, and Clinical Outcome

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                            ICU Patients With COVID-19(n = 9)   Hospitalized COVID-19 Patients(n = 7)   Total Cohort (n = 16)   Between-Group\
                                                                                                                                                                *P*Value
  --------------------------------------------------------- ----------------------------------- --------------------------------------- ----------------------- ----------------
  Demographics                                                                                                                                                  

  Age (y)                                                   66 \[62, 77\]                       71 \[55, 73\]                           68 \[59, 75\]           .98

  Gender (male, %)                                          6 (67)                              6 (86)                                  12 (75)                 .59

  Body mass index                                           26.9 \[26.0, 27.8\]                 26.3 \[24.4, 27.9\]                     26.6 \[25.1, 27.9\]     .59

  APACHE-II score (first 24 h)                              30 \[25, 32\]                       \-                                      \-                      \-

  SAPS II score (first 24 h)                                69 \[66, 78\]                       \-                                      \-                      \-

  SOFA score (baseline)                                     13 \[13, 15\]                       \-                                      \-                      \-

  Comorbidity data                                                                                                                                              

  Charlson comorbidityindex(total score)                    3 \[2, 6\]                          \-                                      \-                      \-

  Myocardial infarction (no./%)                             1 (11%)                             \-                                      \-                      \-

  Chronic heart failure (no./%)                             0 (0%)                              \-                                      \-                      \-

  Peripheral vascular disease (no./%)                       1 (11%)                             \-                                      \-                      \-

  Cerebrovascular accident (no./%)                          1 (11%)                             \-                                      \-                      \-

  Dementia (no./%)                                          0 (0%)                              \-                                      \-                      \-

  COPD (no./%)                                              3 (33%)                             \-                                      \-                      \-

  Connective tissue disease (no./%)                         0 (0%)                              \-                                      \-                      \-

  Peptic ulcer disease (no./%)                              0 (0%)                              \-                                      \-                      \-

  Liver disease (0--3) (no./%)                              0 (0%)                              \-                                      \-                      \-

  Diabetes (0--2) (no./%)                                   2 (22%)                             \-                                      \-                      \-

  Hemiplegia (no./%)                                        0 (0%)                              \-                                      \-                      \-

  Moderate to severe CKD (no./%)                            2 (22%)                             \-                                      \-                      \-

  Solid tumor (0--6) (no./%)                                0 (0%)                              \-                                      \-                      \-

  Leukemia (no./%)                                          0 (0%)                              \-                                      \-                      \-

  Lymphoma (no./%)                                          0 (0%)                              \-                                      \-                      \-

  HIV/AIDS (no./%)                                          0 (0%)                              \-                                      \-                      \-

  Laboratory data                                                                                                                                               

  C-reactive protein (mg/L)                                 149 \[96, 243\]                     43 \[7, 126\]                           120 \[31, 197\]         .07

  Procalcitonin levels (ng/mL)                              0.4 \[0.2, 1.2\]                    0.2 \[0.1, 0.3\]                        0.3 \[0.2, 0.5\]        .09

  Total leukocyte count (G/L)                               7.0 \[4.7, 7.7\]                    6.9 \[5.2, 8.5\]                        6.9 \[5.0, 8.1\]        .92

  Total lymphocyte count (G/L)                              0.8 \[0.6, 0.9\]                    1.2 \[1.0, 1.9\]                        1.0 \[0.8, 1.7\]        .06

  Platelet count (G/L)                                      192 \[143, 225\]                    185 \[174, 267\]                        189 \[166; 234\]        .47

  Serum potassium (mmol/L)                                  3.9 \[3.6, 4.2\]                    3.7 \[3.6, 4.2\]                        3.8 \[3.6, 4.2\]        .42

  Serum creatinine (µmol/L)                                 102 \[76, 134\]                     79 \[62, 97\]                           95 \[67, 105\]          .14

  D-dimers(µg/L)                                            1340 \[982, 1973\]                  490 \[428, 2062\]                       1233\[574, 2062\]       .28

  Follow-up                                                                                                                                                     

  Days on ICU                                               11.8 \[8.3, 23.0\]                  \-                                      \-                      \-

  Days in hospital                                          17 \[9, 24\]                        6 \[4, 14\]                             10.5 \[4.5, 20.0\]      .07

  Total days on antibiotics                                 6 \[4, 8\]                          4 \[1, 12\]                             4.5 \[1.5, 9.0\]        .49

  Total days on mechanical ventilation                      9 \[5, 23\]                         \-                                      \-                      \-

  Renal replacement at any time(no./%)                      3 (33%)                             \-                                      \-                      \-

  On vasopressors at any time(no./%)                        8 (89%)                             \-                                      \-                      \-

  Total norepinephrine dose(cumulative dose/ICU days; mg)   3.4 \[1.3, 6.8\]                    \-                                      \-                      \-

  ICU mortality (no./%)                                     2/7 (29%)^a^                        \-                                      \-                      \-

  Hospital mortality (no./%)                                2/7 (29%)^a^                        0 (0%)                                  2/14 (14%)              .46
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Demographical data, baseline comorbidities, laboratory data, and clinical follow-up are given for patients with primary admission to ICU versus normal ward (until censor date). Numbers (No.) with percentages are given, as indicated. Continuous data are reported as median \[quartiles\]. Between-group*P v*alues fromMann-Whitney*U* tests and Fisher exact tests are given for ICU versus non--ICU (normal ward) populations.

Abbreviations: AIDS, acquired immunodeficiency syndrome; APACHE-II, Acute Physiology and Chronic Health Evaluation-II score; CKD, xxx; COPD, chronic obstructive pulmonary disease; COVID-19, Coronavirus Disease 2019; HIV, human immunodeficiency virus; ICU, intensive care unit;SAPSII,Simplified Acute Physiology ScoreII;SOFA,Sepsis-related organ failure assessment score.

^a^Mortality data are available from 7 ICU patients. Between-group *P* values are given for ICU versus non--ICU (normal ward) populations.

mHLA-DR expression at admission was significantly lower in the ICU group (9280antibodies/cell \[6114, 16,567\]) as compared to the non--ICU group (30,900 antibodies/cell \[26,777, 52,251\]), with a median difference of 21,508 antibodies/cell (95% CI, 14,118--42,971), *P*=.002 (Figure [2](#F2){ref-type="fig"}). Similarly, the adjusted quantile regression and linear regression provided evidence for a significant between-group difference (*P*=.001 and *P*\<.001, respectively).

![mHLA-DR expression in hospitalized patients with COVID-19. mHLA-DR expression (given in Ab/cell) at normal ward (n = 7) versus primary ICU admission (n=9), *P*=.002 in Mann-Whitney *U* test. Ab/cell indicates antibodies/cell; COVID-19, Coronavirus Disease 2019; ICU, intensive care unit; mHLA-DR, monocytic human leukocyte antigen-DR.](ane-publish-ahead-of-print-10.1213.ane.0000000000005044-g002){#F2}

The sensitivity analysis, in which 1 patient of the non--ICU group was counted toward the ICU group as described above, provides consistent results in the unadjusted analysis (median difference 19,419 antibodies/cell, 95% CI, 8487--43,578, *P*=.016) as well as in the adjusted analyses (*P*=.001 and *P*=.007, respectively).

In ICU patients, median mHLA-DR expression was 9280 antibodies/cell \[6114, 16,567\] at admission (N=9), 9672 antibodies/cell \[8253, 10,511\] at 3 days (N=9), and 7334 antibodies/cell \[5241, 11,022\] at 5 days (N=6), without evidence for a change over time (*P*=.33, Figure [3](#F3){ref-type="fig"}). Including the admissionmeasurement of the patient who was initially admitted to the normal ward and who was later admitted to the ICU, median HLA-DR expression was 9944 antibodies/cell \[6114, 16,782\] at admission (N=10), still without evidence for a change over time (*P*=.19).

![Expression of monocytic HLA-DR over time in patients hospitalized in the ICU. Available data (presented in Ab/cell) are given at ICU admission, and days 3 and 5. Discharge from ICU (until day 5) and transfer from the normal ward to ICU are included. Ab/cell indicates antibodies/cell; HLA-DR, human leukocyte antigen-DR; ICU, intensive care unit.](ane-publish-ahead-of-print-10.1213.ane.0000000000005044-g003){#F3}

Discussion
==========

We demonstrate immunosuppression of key innate immune cells in critically ill patients with (severe) COVID-19. mHLA-DR expression was reduced on circulating CD14+ cells, and this was not observed in hospitalized COVID-19 patients without critical illness.Importantly, this initial effect persisted over the ensuing days of ICU treatment (until day 5). Of note, all study individuals were treatment-naiveregarding immunomodulatory agents and/ or high-dose corticosteroids. In the light of the current multiple immunomodulatory interventional approaches tested in COVID-19,^[@R25]^ it seems essential that patients are adequately immunologically characterized using immunological read-outs in an effort to determine which patient might benefit best from a given immunomodulatory intervention. Thus, injury-associated immunosuppression should be taken into account when novel immunomodulatory interventions are designed and tested in critically ill patients with COVID-19.

Our current data show that immunosuppression presented as early as at ICU admission and the observed downregulation of mHLA-DR did not change significantly over the ensuing days of ICU treatment (ie, at least until day 5 after ICU admission). This seems of particular interest, as when compared to ICU patients with (bacterial) septic shock, decreased mHLA-DR expression is mostly observed after a few days following ICU admission and may be most prominent after about 72 hours (reviewed in reference[@R3]). Although the exact onset of disease can mostly not be elucidated in critically ill patients, it is known that the median incubation period of SARS-CoV-2 is about 4--5 days^[@R21]--[@R24]^ and about 97.5% of patients diagnosed with COVID-19 develop symptoms within the first 11.5 days.^[@R22]^ In the light of the specific disease investigated, it thus seems tempting to speculate that downregulation of mHLA-DR would typically occur before development of acute respiratory failure, that is, before ICU admission in severe COVID-19 disease and mHLA-DR assessment could theoretically provide early prognostic information. Moreover, and importantly, the immunosuppression reflected in decreased mHLA-DR might theoretically be a relevant contributor to progression of increased viral replication and/or the severity of the viral disease. Previous data from ICU patients with bacterial septic shock show that secondary infection rates are increased in patients with persistent downregulation of mHLA-DR, that is, injury-associated immunosuppression (reviewed in references[@R3], [@R6]). Thus, as secondary infections contribute to increased morbidity and mortality in ICU patients with COVID-19 disease, the potential association of mHLA-DR downregulation with secondary infection rates should be investigated in subsequent investigations. Importantly, however, in the current analysis, we are unable to conclude back on causality and/or effects on secondary infection rates due to the limited sample size and the preliminary, observational nature of the investigation.

Further, our observations might challenge the concept of a general macrophage activation syndrome as being a primary driver of severe COVID-19 disease. In the current observational study, we observed macrophage "deactivation" as indicated by reduced expression of MHC class II (human leukocyte antigen-DR \[HLA-DR\]) on CD14+ cells, rather than macrophage activation. However, due to the limited sample size and monocentric character of the investigation, this awaits confirmation in subsequent larger analyses.

A number of additional limitations of this analysis deserve discussion. First, consecutive patients were included in a single-center observational study and all respective limitations (driven by study design) apply. Second, the sample size was limited and results await confirmation in subsequent larger cohorts. However, the limited sample size was partly due to the fact that informed consent cannot easily be achieved during a pandemic in the cohort investigated. Nevertheless, observed effects on mHLA-DR expression were consistent and strong, likely pointing to an important disease-immanent process. Third, final outcome data werenot available for 3 patients with long-term ICU stay. However, although a final data set might have been preferable, it may underline the relevance of immunosuppression in this context. Fourth, follow-up data at days 3 and 5 of noncritically ill hospitalized patients would have been interesting, but were unavailable (also for the fact that patients improved rapidly) to obtain such samples as patients were discharged from our institution. Fifth, longer follow-up, that is, until all ICU patients have recovered, would have been preferable;however, this was initially deemed not possible and out of the scope of the current investigation. Nevertheless, we are therefore unable to conclude on the potential recovery slope of mHLA-DR in survivors of critical illness and suppose that this should be investigated in subsequent larger studies. Sixth, one might speculate whether monocyte deactivation would be a phenomenon of the blood compartment, rather than to reflect monocytic immune function in "solid immune organs." However, it was previously shown in patients with bacterial sepsis, that HLA-DR downregulation would not only be observed in the blood compartment but would rather be paralleled in respective "solid immune organs."^[@R15]^

In conclusion, in a prospective monocentric study with a limited sample size, we observed that severe COVID-19 disease is associated with considerable and sustained immunosuppression of key innate immune cells (monocytes/macrophages), indicating a dysfunctional immune response in a majority of critically ill patients. This phenotype persisted over the initial days of ICU treatment and may underline the urgent need for an adequate immunological characterization (using appropriate immunological read-outs) when targeted immunomodulatory interventions are tested in respective critically ill patients.
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